Novel agents in development for multidrug-resistant Gram-negative infections: potential new options facing multiple...

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Multidrug-resistant (MDR) Gram-negative bacterial infections pose a significant global health threat.
• There is an urgent need for novel anti-infective agents to overcome existing resistance mechanisms.

Approach:

• Review of four novel anti-infective agents in development: tebipenem, durlobactam-sulbactam, cefepime-taniborbactam, and xeruborbactam.
• Analysis of their development phases, in-vitro activity, and clinical trial data, particularly for complicated urinary tract infections and drug-resistant Acinetobacter baumannii.

Key Points:

• Tebipenem: Oral carbapenem, completed Phase III for complicated urinary tract infections.
• Durlobactam-sulbactam: Potential treatment for drug-resistant Acinetobacter baumannii.
• Cefepime-taniborbactam: In-vitro potency against challenging pathogens; awaiting further data.
• Xeruborbactam: Broad-spectrum beta-lactamase inhibitor with enhanced in-vitro activity against MDR pathogens; limited human data.

Conclusions:

• Novel agents exhibit diverse in-vitro activity profiles against challenging Gram-negative pathogens.
• Some agents offer both oral and intravenous formulations, expanding treatment options.
• Clinical development varies, with some agents having completed Phase III trials and others in earlier stages.